TVGNW — Tevogen Bio Holdings Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1860871 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,400,920 | -5,446,255 | 4,921,005 | 692,305 | 14,763,163 |
| Dec 2025 | 0 | — | -4,610,201 | -4,677,580 | 4,382,994 | 552,372 | 12,617,720 |
| Sep 2025 | 0 | — | -5,729,431 | -5,726,812 | 4,493,669 | 1,037,094 | 12,317,565 |
| Jun 2025 | 0 | — | -5,444,536 | -5,503,979 | 4,269,136 | 685,229 | 13,753,878 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,328,577
Investing CF
$0
Financing CF
$11,662,393
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-139,660,549
Inventory
—
Receivables
$158,819
ST Investments
—
EBIT TTM
$-26,058,404
Pretax Income TTM
$-26,275,432
Interest Exp TTM
$173,383
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,140,515 | -26,275,432 | 4,382,994 | 12,617,720 | — | -12,328,577 |
| Dec 2024 | 0 | -53,564,488 | -13,727,380 | 3,461,675 | 10,135,680 | — | -11,998,730 |
| Dec 2023 | 0 | -8,843,025 | -60,477,680 | 5,505,503 | 99,934,400 | — | -8,171,118 |
| Dec 2022 | 0 | -953,083 | 4,408,361 | 357,138,356 | 15,057,704 | — | -215,395 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $181.31B | $335.94 | — |
| GILD | GILEAD SCIENCES, INC. | $166.04B | $133.73 | — |
| ARGX | ARGENX SE | $50.27B | $808.43 | — |
| RVMD | Revolution Medicines, Inc. | $32.93B | $154.89 | — |
| BIIB | BIOGEN INC. | $28.51B | $193.08 | — |
News headlines (Yahoo Finance, 1h cache)
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth
2026-03-26 16:45 · Yahoo
Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-03-25 18:20 · Yahoo
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)
2026-03-18 16:22 · Yahoo
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
2025-11-14 19:32 · Yahoo
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
2025-11-05 20:20 · Yahoo
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
2025-11-03 19:45 · Yahoo
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
2025-10-29 16:35 · Yahoo
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
2025-10-15 19:50 · Yahoo
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
2025-09-25 12:30 · Yahoo
Tevogen highlights potential role of TVGN 489 on impact of Long COVID
2025-09-24 12:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.